Cytocore Inc (CYOE) 0.0310 $CYOE
MEDITE Signs OEM Agreement With a Leading Anatomical Pathology Company
Marketwire - Wed Apr 23, 6:02AM CDT
MEDITE Group, a leading developer and manufacturer of innovative, high-quality equipment and supplies for histology, pathology and cytology laboratories, has signed an OEM agreement with a leading anatomical pathology company to distribute MEDITE's proprietary high transparency coverslipping film to be used in all Tape-Coverslipper machines. MEDITE's branded CytoTape is manufactured in Germany and was commercially launched in 2013. It was specifically designed for perfect optical characteristics, long durability and the ability to withstand higher temperatures. Tape-Coverslippers can process up to 1,200 microscopic slides per hour compared to up to 400 slides per hour for standard glass coverslippers, a key advantage for high volume labs in the cancer diagnostic segments of cytology and histology.
MEDITE Group and CytoCore, Inc. Announce Closing of Acquisition
Marketwire - Fri Apr 04, 6:30AM CDT
MEDITE, a leading developer of innovative, high-quality equipment and supplies for the cancer diagnostic segments of histology, pathology and cytology today announced it has closed the acquisition transaction with CytoCore, Inc. (OTCBB: CYOE), a late development stage bio molecular diagnostics company engaged in the design, development, and commercialization of cost-effective sample collection, clinical laboratory assay and instrument systems for the early detection and classification of cancer and for the assessment of the risk for cancer progression. In conjunction with the closing of the acquisition, the companies also announced the initial closing of a private placement of common stock resulting in gross cash proceeds to the Company of $1.5 million.
MEDITE Signs Exclusive Marketing and Distribution Agreement With Medline
Marketwire - Thu Jan 16, 10:30AM CST
MEDITE Inc., a leading developer and manufacturer of innovative, high-quality equipment and supplies for histology, pathology and cytology laboratories, announced an exclusive marketing and distribution agreement with Medline Industries, Inc., based in Mundelein, Illinois. Under the agreement, Medline will have exclusive rights to market and distribute MEDITE's histology equipment and consumable product portfolio in the U.S. & Canada.
CytoCore to Acquire MEDITE
Marketwire - Mon Jan 13, 9:15AM CST
MEDITE Group, a leading developer of innovative, high-quality equipment and supplies for the cancer diagnostic segments of histology, pathology and cytology headquartered in Orlando, Florida, today announced that it has signed a definitive purchase agreement to be acquired by Chicago-based CytoCore, Inc. (OTCBB: CYOE), a late development stage bio molecular diagnostics company engaged in the design, development, and commercialization of cost-effective sample collection, clinical laboratory assay and instrument systems for the early detection and classification of cancer and for the assessment of the risk for cancer progression. The purchase agreement has been approved by the Board of Directors of both companies and is subject to standard and customary closing conditions and deliveries. The transaction is currently expected to close by March 15, 2014.
MEDITE Signs OEM Agreement With a Leading Anatomical Pathology Company
Marketwire - Wed Apr 23, 6:02AM CDT
MEDITE Group, a leading developer and manufacturer of innovative, high-quality equipment and supplies for histology, pathology and cytology laboratories, has signed an OEM agreement with a leading anatomical pathology company to distribute MEDITE's proprietary high transparency coverslipping film to be used in all Tape-Coverslipper machines. MEDITE's branded CytoTape is manufactured in Germany and was commercially launched in 2013. It was specifically designed for perfect optical characteristics, long durability and the ability to withstand higher temperatures. Tape-Coverslippers can process up to 1,200 microscopic slides per hour compared to up to 400 slides per hour for standard glass coverslippers, a key advantage for high volume labs in the cancer diagnostic segments of cytology and histology.
MEDITE Group and CytoCore, Inc. Announce Closing of Acquisition
Marketwire - Fri Apr 04, 6:30AM CDT
MEDITE, a leading developer of innovative, high-quality equipment and supplies for the cancer diagnostic segments of histology, pathology and cytology today announced it has closed the acquisition transaction with CytoCore, Inc. (OTCBB: CYOE), a late development stage bio molecular diagnostics company engaged in the design, development, and commercialization of cost-effective sample collection, clinical laboratory assay and instrument systems for the early detection and classification of cancer and for the assessment of the risk for cancer progression. In conjunction with the closing of the acquisition, the companies also announced the initial closing of a private placement of common stock resulting in gross cash proceeds to the Company of $1.5 million.
MEDITE Signs Exclusive Marketing and Distribution Agreement With Medline
Marketwire - Thu Jan 16, 10:30AM CST
MEDITE Inc., a leading developer and manufacturer of innovative, high-quality equipment and supplies for histology, pathology and cytology laboratories, announced an exclusive marketing and distribution agreement with Medline Industries, Inc., based in Mundelein, Illinois. Under the agreement, Medline will have exclusive rights to market and distribute MEDITE's histology equipment and consumable product portfolio in the U.S. & Canada.
CytoCore to Acquire MEDITE
Marketwire - Mon Jan 13, 9:15AM CST
MEDITE Group, a leading developer of innovative, high-quality equipment and supplies for the cancer diagnostic segments of histology, pathology and cytology headquartered in Orlando, Florida, today announced that it has signed a definitive purchase agreement to be acquired by Chicago-based CytoCore, Inc. (OTCBB: CYOE), a late development stage bio molecular diagnostics company engaged in the design, development, and commercialization of cost-effective sample collection, clinical laboratory assay and instrument systems for the early detection and classification of cancer and for the assessment of the risk for cancer progression. The purchase agreement has been approved by the Board of Directors of both companies and is subject to standard and customary closing conditions and deliveries. The transaction is currently expected to close by March 15, 2014.
